Marc van Dijk

Marc van Dijk currently serves as the Chief Scientific Officer for Discovery and Engineering at FairJourney Biologics since December 2024. Prior to this role, Marc held the position of Chief Scientific Officer at MiNK Therapeutics from March 2022 to December 2024, overseeing research teams in Cambridge, UK, and Lexington, MA. Marc's extensive career includes significant roles at Agenus as Chief Technology Officer and Executive Director of Platform Technology, leading platform technology initiatives at AgenTus Therapeutics, and contributions as Vice President of Antibody Technology at Genmab. Academic credentials include a Postdoctoral degree in Molecular Biology from UC San Diego and a Ph.D. in Molecular Biology from Utrecht University.